Esmail, A.; Hamdaneh, Y.; Khasawneh, B.; Al-Rawi, M.; Al-Najjar, E.; Dhillon, V.; Alhaj, A.; Rayyan, Y.; Abdelrahim, M.
Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience. Biomedicines 2025, 13, 2844.
https://doi.org/10.3390/biomedicines13122844
AMA Style
Esmail A, Hamdaneh Y, Khasawneh B, Al-Rawi M, Al-Najjar E, Dhillon V, Alhaj A, Rayyan Y, Abdelrahim M.
Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience. Biomedicines. 2025; 13(12):2844.
https://doi.org/10.3390/biomedicines13122844
Chicago/Turabian Style
Esmail, Abdullah, Yazan Hamdaneh, Bayan Khasawneh, Maryam Al-Rawi, Ebtesam Al-Najjar, Vikram Dhillon, Ahmad Alhaj, Yaser Rayyan, and Maen Abdelrahim.
2025. "Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience" Biomedicines 13, no. 12: 2844.
https://doi.org/10.3390/biomedicines13122844
APA Style
Esmail, A., Hamdaneh, Y., Khasawneh, B., Al-Rawi, M., Al-Najjar, E., Dhillon, V., Alhaj, A., Rayyan, Y., & Abdelrahim, M.
(2025). Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience. Biomedicines, 13(12), 2844.
https://doi.org/10.3390/biomedicines13122844
